Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

M. Paganin, M. Zecca, G. Fabbri, K. Polato, A. Biondi, C. Rizzari, F. Locatelli, G. Basso

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL). Sixty patients with isolated or combined marrow relapse were studied. All patients belonged to the S3 or S4 groups, as defined by the Berlin-Frankfurt-Münster stratification for relapsed ALL. MRD was studied by real-time quantitative PCR after the first, second and third chemotherapy course (time points 1 (TP1), 2 (TP2) and 3 (TP3), respectively). MRD results, not used for treatment refinement, were categorized as negative (NEG MRD), positive not-quantifiable (POS-NQ MRD) when MRD level was below quantitative range (a level -4) or positive within quantitative range (POS MRD) when MRD level was ≥10-4. With a median observation time of 15 months, overall 3-year event-free survival (EFS) was 27%. The 3-year EFS was 73, 45 and 19% for patients with NEG-MRD, POS NQ-MRD and POS-MRD at TP1, respectively (P

Original languageEnglish
Pages (from-to)2193-2200
Number of pages8
JournalLeukemia
Volume22
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Berlin
Real-Time Polymerase Chain Reaction
Bone Marrow
Observation
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. / Paganin, M.; Zecca, M.; Fabbri, G.; Polato, K.; Biondi, A.; Rizzari, C.; Locatelli, F.; Basso, G.

In: Leukemia, Vol. 22, No. 12, 2008, p. 2193-2200.

Research output: Contribution to journalArticle

Paganin, M. ; Zecca, M. ; Fabbri, G. ; Polato, K. ; Biondi, A. ; Rizzari, C. ; Locatelli, F. ; Basso, G. / Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. In: Leukemia. 2008 ; Vol. 22, No. 12. pp. 2193-2200.
@article{8dd0892ac43b489cbe568adfd453b782,
title = "Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia",
abstract = "The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL). Sixty patients with isolated or combined marrow relapse were studied. All patients belonged to the S3 or S4 groups, as defined by the Berlin-Frankfurt-M{\"u}nster stratification for relapsed ALL. MRD was studied by real-time quantitative PCR after the first, second and third chemotherapy course (time points 1 (TP1), 2 (TP2) and 3 (TP3), respectively). MRD results, not used for treatment refinement, were categorized as negative (NEG MRD), positive not-quantifiable (POS-NQ MRD) when MRD level was below quantitative range (a level -4) or positive within quantitative range (POS MRD) when MRD level was ≥10-4. With a median observation time of 15 months, overall 3-year event-free survival (EFS) was 27{\%}. The 3-year EFS was 73, 45 and 19{\%} for patients with NEG-MRD, POS NQ-MRD and POS-MRD at TP1, respectively (P",
author = "M. Paganin and M. Zecca and G. Fabbri and K. Polato and A. Biondi and C. Rizzari and F. Locatelli and G. Basso",
year = "2008",
doi = "10.1038/leu.2008.227",
language = "English",
volume = "22",
pages = "2193--2200",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

AU - Paganin, M.

AU - Zecca, M.

AU - Fabbri, G.

AU - Polato, K.

AU - Biondi, A.

AU - Rizzari, C.

AU - Locatelli, F.

AU - Basso, G.

PY - 2008

Y1 - 2008

N2 - The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL). Sixty patients with isolated or combined marrow relapse were studied. All patients belonged to the S3 or S4 groups, as defined by the Berlin-Frankfurt-Münster stratification for relapsed ALL. MRD was studied by real-time quantitative PCR after the first, second and third chemotherapy course (time points 1 (TP1), 2 (TP2) and 3 (TP3), respectively). MRD results, not used for treatment refinement, were categorized as negative (NEG MRD), positive not-quantifiable (POS-NQ MRD) when MRD level was below quantitative range (a level -4) or positive within quantitative range (POS MRD) when MRD level was ≥10-4. With a median observation time of 15 months, overall 3-year event-free survival (EFS) was 27%. The 3-year EFS was 73, 45 and 19% for patients with NEG-MRD, POS NQ-MRD and POS-MRD at TP1, respectively (P

AB - The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL). Sixty patients with isolated or combined marrow relapse were studied. All patients belonged to the S3 or S4 groups, as defined by the Berlin-Frankfurt-Münster stratification for relapsed ALL. MRD was studied by real-time quantitative PCR after the first, second and third chemotherapy course (time points 1 (TP1), 2 (TP2) and 3 (TP3), respectively). MRD results, not used for treatment refinement, were categorized as negative (NEG MRD), positive not-quantifiable (POS-NQ MRD) when MRD level was below quantitative range (a level -4) or positive within quantitative range (POS MRD) when MRD level was ≥10-4. With a median observation time of 15 months, overall 3-year event-free survival (EFS) was 27%. The 3-year EFS was 73, 45 and 19% for patients with NEG-MRD, POS NQ-MRD and POS-MRD at TP1, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=57849085208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849085208&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.227

DO - 10.1038/leu.2008.227

M3 - Article

C2 - 18754029

AN - SCOPUS:57849085208

VL - 22

SP - 2193

EP - 2200

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -